Injectable testosterone suppresses natural production, causing infertility. New protocols use shorter-half-life oral/topical testosterone combined with enclomiphene (which blocks estrogen feedback) to increase T-levels while maintaining the body's own production, making it a viable option for younger men concerned about fertility.

Cannabinoids (THC, CBD) don't directly reduce testosterone. Instead, the act of smoking marijuana increases the enzyme aromatase, which converts testosterone into estrogen. Higher estrogen then signals the pituitary to reduce testosterone production, creating an indirect negative feedback loop.

Creatine helps normalize testosterone's conversion pathway, shifting it toward DHT and away from estrogen. For individuals with low 5-alpha reductase activity, it restores a natural balance rather than creating a supraphysiological state that could accelerate hair loss.

The fear that creatine causes hair loss originates from one 2009 study that found increased DHT levels but did not measure actual hair loss. This finding has never been replicated, and subsequent randomized controlled trials show no significant impact on hair outcomes or DHT levels versus a placebo.

Unlike conditions with transient flare-ups, missing a few doses of a fast-acting alopecia drug can cause catastrophic hair loss, erasing years of progress. A long-acting injectable provides a crucial buffer against real-world issues like insurance delays, making it a uniquely superior option for patients despite the injection route.

Viridermix's strategy for its oral hair loss drug isn't just about convenience. The company re-engineered immediate-release minoxidil to provide consistent exposure to hair follicles, aiming to maximize growth while blunting the plasma spikes responsible for the original blood pressure drug's cardiac side effects.

Dr. D'Agostino gives his aging, neutered dogs a Selective Androgen Receptor Modulator (SARM) to stimulate muscle protein synthesis and maintain vitality. This approach is analogous to Testosterone Replacement Therapy (TRT) in humans, aiming to counteract the loss of skeletal muscle mass associated with aging and hormonal changes.

The fear that creatine causes hair loss stems from one 2009 study that measured an increase in a DHT, a hormone linked to hair loss, but did not measure hair loss itself. The study has not been replicated, and there is no robust scientific evidence directly linking creatine supplementation to hair loss.

When using intermittent androgen deprivation, GnRH antagonists like relugolix are preferred over LHRH agonists like leuprolide. Antagonists allow for a much faster recovery of testosterone during off-treatment periods, which is a significant quality-of-life benefit for patients. With agonists, testosterone recovery can sometimes take years.